CompletedInterventionalPhase 1Last updated May 7, 2018

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Overview

ClinicalTrials.gov ID: NCT02210663
Lead Sponsor: AbbVieINDUSTRY
Brief Summary: This is a Phase 1 study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of single agent Veliparib in Japanese subjects with advanced solid tumors.
Study Type: Interventional

Status

Study Record Dates

NCT01617928Completed

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

NCT00892736Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT02483104Completed

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

NCT01123876Completed

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

NCT01853306Completed

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

NCT02033551Completed

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors